Increasing Cases of Retroperitoneal Fibrosis After Covid-19: Case Report, Did She Die Retroperitoneal Fibrosis or Cancer
| dc.contributor.author | Deniz, Gulnihal | |
| dc.contributor.author | Cakir, Murteza | |
| dc.contributor.author | Akyagci, Serpil Bilgin | |
| dc.date.accessioned | 2026-03-26T15:02:40Z | |
| dc.date.available | 2026-03-26T15:02:40Z | |
| dc.date.issued | 2024 | |
| dc.description | Bilgin Akyağcı, Serpil/0009-0003-5035-1917; Deniz, Gülnihal/0000-0002-5944-8841 | en_US |
| dc.description.abstract | This case report details the unfortunate journey of a 59-year-old breast cancer survivor who developed secondary Retroperitoneal Fibrosis (RPF) in 2022. Despite diligent treatment efforts, her condition took a devastating turn when, in June 2023, she was diagnosed not only with persistent RPF but also with advanced liver, omental, and duodenal cancer. Tragically, her condition deteriorated rapidly, leading to her passing on day 41 following her presentation. This case underscores the challenges of diagnosing and treating RPF. It highlights the importance of considering cancer development in advanced RPF cases that do not respond to treatment, often leaving limited options for effective intervention. | en_US |
| dc.identifier.doi | 10.33706/jemcr.1419408 | |
| dc.identifier.issn | 2149-9934 | |
| dc.identifier.uri | https://doi.org/10.33706/jemcr.1419408 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14901/3651 | |
| dc.language.iso | en | en_US |
| dc.publisher | Emergency Medicine Physicians Assoc Turkey | en_US |
| dc.relation.ispartof | Journal of Emergency Medicine Case Reports | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Retroperitoneal Fibrosis | en_US |
| dc.subject | Liver Cancer | en_US |
| dc.subject | Metastasis | en_US |
| dc.subject | Steroid | en_US |
| dc.subject | Azathioprine | en_US |
| dc.title | Increasing Cases of Retroperitoneal Fibrosis After Covid-19: Case Report, Did She Die Retroperitoneal Fibrosis or Cancer | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | Bilgin Akyağcı, Serpil/0009-0003-5035-1917 | |
| gdc.author.id | Deniz, Gülnihal/0000-0002-5944-8841 | |
| gdc.author.wosid | Deniz, Gülnihal/Gza-5661-2022 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | Erzurum Technical University | en_US |
| gdc.description.departmenttemp | [Deniz, Gulnihal] Erzurum Tech Univ, Dept Physiotherapy & Rehabil, Fac Hlth Sci, Erzurum, Turkiye; [Cakir, Murteza] Ataturk Univ, Dept Neurosurg, Fac Med, Erzurum, Turkiye; [Akyagci, Serpil Bilgin] Mudanya Univ, VM Med Pk Bursa Hosp, Dept Gen Surg, Bursa, Turkiye | en_US |
| gdc.description.endpage | 15 | en_US |
| gdc.description.issue | 1 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | N/A | |
| gdc.description.startpage | 12 | en_US |
| gdc.description.volume | 15 | en_US |
| gdc.description.woscitationindex | Emerging Sources Citation Index | |
| gdc.description.wosquality | Q4 | |
| gdc.identifier.openalex | W4391452246 | |
| gdc.identifier.wos | WOS:001209066100005 | |
| gdc.index.type | WoS | |
| gdc.oaire.accesstype | GOLD | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 0.0 | |
| gdc.oaire.influence | 2.3811355E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Clinical Oncology | |
| gdc.oaire.keywords | Retroperitoneal Fibrosis;Liver Cancer;Metastasis;Steroid;Azathioprine. | |
| gdc.oaire.keywords | Clinical Sciences (Other) | |
| gdc.oaire.keywords | Klinik Onkoloji | |
| gdc.oaire.keywords | Klinik Tıp Bilimleri (Diğer) | |
| gdc.oaire.popularity | 2.2424942E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0302 clinical medicine | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 0.0 | |
| gdc.openalex.normalizedpercentile | 0.02 | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.mendeley | 3 | |
| gdc.wos.citedcount | 0 |